TGTX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving TG Therapeutics, Inc.

August 09, 2022 10:12 AM EDT | Source: Vincent Wong Esq.

New York, New York--(Newsfile Corp. - August 9, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased TG Therapeutics, Inc. ("TG Therapeutics") (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/tgtx-lawsuit-loss-submission-form?prid=30705&wire=5

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7094/133260_685784_logo.jpg

Allegations against TGTX include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

If you suffered a loss in TG Therapeutics you have until September 16, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/133260

info